Azenta
AZTA
35.89
-3.46
-8.79%
Azenta
US · AZTA
#2893 by market cap
Listed 1970
35.89
-3.46
-8.79%
Live - 5344 symbols - heartbeat 468s ago
· 2026-10-08 07:20
Pre-market
35.70
-0.53%
After-hours
36.32
+1.20%
Overnight
35.89
0.00%
- Market cap
- 1.57B
- P/E (TTM)i
- -13.34
- P/Bi
- 1.04
- EPSi
- -1.22
- Div yieldi
- 0.00%
- 52W posi
- 65%
Reader sentiment
Are you bullish or bearish on AZTA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.33, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +3.55% YoY
Margins
- Gross margin
- 45.52%
- Operating margin
- -3.65%
- Net margin
- -9.39%
Key ratios & quality
- Altman Z-Scorei
- 4.33
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 631.56M | 334.18M | 388.54M | 513.70M | 555.50M | 551.49M | 573.45M | 593.82M |
| Gross profit | 246.08M | 134.60M | 172.15M | 243.81M | 255.58M | 239.21M | 254.62M | 270.28M |
| Selling & admin expenses | 167.02M | 163.33M | 190.26M | 252.10M | 251.47M | 263.74M | 262.96M | 261.56M |
| Research & development | 46.94M | 17.32M | 17.82M | 22.41M | 27.54M | 32.14M | 31.52M | 30.39M |
| Operating profit | 32.12M | -46.04M | -35.93M | -30.70M | -23.42M | -56.67M | -39.86M | -21.67M |
| Pretax profit | 20.47M | -83.96M | -40.29M | -48.97M | -9.94M | -20.01M | -19.13M | -7.14M |
| Tax | -47.25M | -22.83M | -13.93M | -20.10M | 1.35M | -11.97M | 5.24M | -31.60M |
| Net profit | 116.46M | 437.42M | 64.85M | 110.75M | 2.13B | -14.64M | -164.90M | -55.76M |
| Basic EPS | 2 | 6 | 1 | 1 | 28 | 0 | -3 | -1 |
| Diluted EPS | 1.64 | 6.04 | 0.88 | 1.49 | 28.48 | -0.22 | -3.10 | -1.22 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 143.34M | 143.86M | 159.19M | 148.64M | 144.80M | 161.18M |
| Gross profit | 62.78M | 66.40M | 72.27M | 63.71M | 62.04M | 72.36M |
| Selling & admin expenses | 69.80M | 60.08M | 61.71M | 60.61M | 67.89M | 67.17M |
| Research & development | 7.60M | 7.42M | 8.26M | 9.19M | 9.43M | 8.85M |
| Operating profit | -14.61M | -1.10M | 2.31M | -6.09M | -15.29M | -3.67M |
| Pretax profit | -12.55M | 2.30M | 6.30M | -2.06M | -157.34M | 846.00K |
| Tax | 7.24M | 2.64M | -45.35M | 3.13M | -323.00K | 2.38M |
| Net profit | -47.66M | -47.99M | 50.88M | -15.43M | -160.80M | 2.46M |
| Basic EPS | -1 | -1 | 1 | 0 | -3 | 0 |
| Diluted EPS | -1.04 | -1.05 | 1.02 | -0.34 | -3.49 | 0.05 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 564.06M | 647.15M | 649.45M | 777.37M | 2.46B | 1.42B | 833.03M | 708.34M |
| Cash & ST investments | 243.99M | 335.77M | 250.70M | 227.51M | 1.57B | 1.02B | 431.19M | 340.92M |
| Inventory | 96.99M | 99.45M | 37.13M | 60.40M | 85.54M | 128.20M | 71.32M | 74.96M |
| Total assets | 1.10B | 1.52B | 1.56B | 1.82B | 3.72B | 2.89B | 2.10B | 2.06B |
| Total current liabilities | 164.62M | 272.27M | 211.12M | 345.09M | 230.55M | 210.93M | 206.09M | 237.67M |
| Short-term debt | 2.00M | 829.00K | 827.00K | -- | -- | -- | -- | -- |
| Long-term debt | 194.07M | 50.32M | 49.59M | 49.68M | -- | -- | -- | -- |
| Total liabilities | 377,425,000.00 | 377,045,000.00 | 345,651,000.00 | 494,178,000.00 | 352,736,000.00 | 351,220,000.00 | 332,418,000.00 | 332,596,000.00 |
| Total equity | 717.83M | 1.14B | 1.21B | 1.33B | 3.36B | 2.53B | 1.77B | 1.73B |
| Retained earnings | -994.07M | -586.41M | -551.07M | -470.05M | 1.66B | 1.64B | 1.48B | 1.42B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 710.60M | 678.48M | 708.34M | 779.90M | 726.99M | 681.35M |
| Cash & ST investments | 328.34M | 318.86M | 340.92M | 409.66M | 380.52M | 325.80M |
| Inventory | 83.32M | 80.51M | 74.96M | 82.46M | 78.51M | 79.08M |
| Total assets | 2.04B | 2.02B | 2.06B | 2.07B | 1.90B | 1.88B |
| Total current liabilities | 220.71M | 245.44M | 237.67M | 267.21M | 257.19M | 272.57M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 340,433,000.00 | 345,501,000.00 | 332,596,000.00 | 359,603,000.00 | 349,212,000.00 | 366,082,000.00 |
| Total equity | 1.70B | 1.67B | 1.73B | 1.71B | 1.55B | 1.51B |
| Retained earnings | 1.42B | 1.37B | 1.42B | 1.40B | 1.24B | 1.25B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 73.96M | 90.90M | 37.87M | 149.86M | -466.05M | 5.83M | 49.74M | 72.18M |
| Depreciation & amortization | 37.43M | 54.45M | 65.50M | 65.33M | 53.70M | 85.58M | 90.74M | 61.21M |
| Free cash flow | 61.18M | 67.04M | -2.06M | 97.05M | -543.48M | -33.60M | 12.35M | 38.32M |
| Dividends paid | -28.29M | -28.90M | -29.51M | -29.73M | -7.49M | -- | -- | -- |
| Stock buybacks / issuance | 2.83M | 3.42M | 4.60M | 5.81M | 5.25M | -834.89M | -658.42M | 2.77M |
| Ending cash balance | 197.71M | 305.17M | 302.53M | 285.33M | 1.04B | 684.05M | 320.99M | 296.69M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 14.40M | 25.81M | 2.17M | 20.85M | 12.18M | 2.77M |
| Depreciation & amortization | 13.95M | 14.72M | 14.43M | 13.65M | 14.00M | 13.58M |
| Free cash flow | 7.00M | 14.97M | -5.69M | 14.66M | 4.78M | -3.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 1.22M | -- | -- | -50.05M |
| Ending cash balance | 288.87M | 293.82M | 296.69M | 351.99M | 249.29M | 204.67M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 17.59 | 47.12 | 5.51 | 8.72 | 90.98 | -0.48 | -7.63 | -3.19 |
| ROA %i | 12.52 | 33.50 | 4.22 | 6.56 | 77.06 | -0.43 | -6.59 | -2.68 |
| ROIC %i | 14.22 | 43.02 | 5.36 | 8.23 | 87.79 | -1.56 | -8.90 | -3.87 |
| 5-year avg ROE %i | 4.76 | 13.20 | 13.86 | 17.95 | 33.98 | 30.37 | 19.41 | 17.67 |
| EBIT margin %i | 4.75 | 4.06 | 8.68 | -9.14 | -0.96 | -4.58 | -11.11 | -3.65 |
| FCF / sales %i | 9.69 | 8.59 | -- | 18.89 | -- | -- | 1.97 | 6.45 |
| Current ratioi | 3.43 | 2.38 | 3.08 | 2.25 | 10.67 | 6.73 | 4.04 | 2.98 |
| Quick ratioi | 2.24 | 1.84 | 1.64 | 1.01 | 7.52 | 5.57 | 2.96 | 2.07 |
| Debt / assetsi | 17.90 | 3.37 | 4.45 | 5.21 | 1.32 | 2.09 | 2.70 | 2.49 |
| LT debt / equityi | 27.04 | 4.42 | 5.64 | 7.15 | 1.46 | 2.38 | 3.21 | 2.97 |
| Interest coveragei | 3.15 | 1.42 | 26.47 | -23.04 | -1.17 | -- | -- | -- |
| Revenue CAGR (3Y) %i | 4.55 | -8.34 | -9.69 | -6.65 | 18.46 | 12.38 | 3.74 | 2.25 |
| Net income CAGR (3Y) %i | 101.63 | -- | 1.18 | -1.70 | 69.57 | -- | -- | -- |
| FCF CAGR (3Y) %i | 30.41 | 35.92 | -- | 16.63 | -- | -- | -49.70 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -3.33 | -6.09 | -3.19 | -3.51 | -10.65 | -7.72 |
| ROA %i | -2.84 | -5.14 | -2.68 | -2.93 | -8.79 | -6.31 |
| ROIC %i | -4.06 | -5.91 | -3.87 | -4.22 | -11.15 | -7.47 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -9.68 | -8.87 | -3.65 | -3.28 | -3.38 | -3.70 |
| FCF / sales %i | 5.84 | 7.89 | 6.45 | 5.20 | 4.81 | 1.61 |
| Current ratioi | 3.22 | 2.76 | 2.98 | 2.92 | 2.83 | 2.50 |
| Quick ratioi | 2.16 | 1.81 | 2.07 | 2.10 | 2.02 | 1.74 |
| Debt / assetsi | 2.63 | 2.61 | 2.49 | 2.63 | 2.93 | 2.88 |
| LT debt / equityi | 3.16 | 3.14 | 2.97 | 3.18 | 3.58 | 3.57 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Sample Management Solutions is the largest reported line at 54.78% of revenue, across 2 reported segments.
- Multiomics follows at 45.22%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Sample Management Solutions54.78%
Multiomics45.22%
Quote time 2026-10-08 07:20:54 · For reference only, not investment advice and not tailored to your situation.